Australia Advises 475,000 Bowel Cancer Retests After Kits Questioned
This article was originally published in PharmAsia News
Executive SummaryAustralia's Health Department has advised nearly half a million patients to undergo new tests for bowel cancer after kits they used came under question. The department said the tests in question, supplied by Dorevitch Pathology, returned a possibly excessive amount of negative results. Suspicions were raised about the test when the level of positive results, more than 100,000 since last December, was lower than expected. The government plans to notify the 475,000 people who have used the self-test bowel kits since Dec. 1, 2008, advising them to be retested. (Click here for more
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.